Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of “Buy” by Analysts

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has received an average recommendation of “Buy” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $61.38.

Several equities analysts have recently commented on the company. Wedbush reiterated an “outperform” rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. William Blair assumed coverage on Corbus Pharmaceuticals in a research note on Friday. They set an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Corbus Pharmaceuticals in a research note on Tuesday, February 18th. Piper Sandler assumed coverage on Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an “overweight” rating and a $35.00 target price for the company. Finally, StockNews.com upgraded Corbus Pharmaceuticals to a “sell” rating in a research note on Monday, January 13th.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CRBP. Vestcor Inc acquired a new stake in Corbus Pharmaceuticals in the third quarter worth $64,000. Wells Fargo & Company MN increased its position in Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 2,195 shares during the period. Avanza Fonder AB acquired a new stake in Corbus Pharmaceuticals in the fourth quarter worth $84,000. Deutsche Bank AG increased its position in Corbus Pharmaceuticals by 46.8% in the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 2,616 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in Corbus Pharmaceuticals in the fourth quarter worth $101,000. 64.64% of the stock is owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Trading Down 7.8 %

Corbus Pharmaceuticals stock opened at $6.96 on Tuesday. The stock has a market cap of $84.77 million, a P/E ratio of -1.48 and a beta of 2.63. The stock has a 50 day moving average of $10.47 and a 200-day moving average of $21.71. Corbus Pharmaceuticals has a 52 week low of $6.78 and a 52 week high of $61.90.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.